key: cord-0763321-32d40l8u authors: Aoi, Shunsuke; Kakkar, Amit M; Golowa, Yosef; Grushko, Michael; Coyle, Christina M; Elrafei, Tarek; Langston, Matthew D; Faillace, Robert T; Bangalore, Sripal; Sokol, Seth I title: Saddle pulmonary embolism and clot in transit in COVID-19 infection: a case report of catastrophic venous thromboembolism date: 2020-12-07 journal: Eur Heart J Case Rep DOI: 10.1093/ehjcr/ytaa437 sha: b6a6bd3a9f5ab0597072ed4808b538b4818d703e doc_id: 763321 cord_uid: 32d40l8u BACKGROUND : Coronavirus disease 2019 (COVID-19) is associated with a coagulopathy favouring thrombosis over bleeding that imparts a poor prognosis. Clot in transit (CIT) is considered a rare entity and the most severe form of venous thromboembolism (VTE), carrying a higher mortality than isolated pulmonary embolism (PE). The incidence of this phenomenon in patients with COVID-19 infection is unknown and likely under-recognized. CASE SUMMARY : During the peak of the COVID-19 pandemic in New York City, a 70-year-old Hispanic female presented with syncope due to a saddle PE further complicated by a highly mobile CIT. Polymerase chain reaction was positive for COVID-19 infection, however, there was no evidence of lung parenchymal involvement or hyper-inflammation. Based on consensus from a multidisciplinary team, aspiration thrombectomy was attempted to treat this extreme case of VTE, however, the patient died during the procedure. DISCUSSION : This case raises awareness to the most catastrophic form of VTE, presenting in an early phase of COVID-19 infection without the typical hyper-inflammation and severe lung injury associated with development of COVID-related coagulopathy. It also serves to inform on the critical role echocardiography has in the comprehensive evaluation and re-evaluation of hospitalized patients with COVID-19, and the importance of a multidisciplinary organized approach in clinical decision-making for this complex and poorly understood disease and its sequelae. Coronavirus disease 2019 (COVID-19) is associated with a coagulopathy favouring thrombosis over bleeding that imparts a poor prognosis. Clot in transit (CIT) is considered a rare entity and the most severe form of venous thromboembolism (VTE), carrying a higher mortality than isolated pulmonary embolism (PE). The incidence of this phenomenon in patients with COVID-19 infection is unknown and likely under-recognized. During the peak of the COVID-19 pandemic in New York City, a 70-year-old Hispanic female presented with syncope due to a saddle PE further complicated by a highly mobile CIT. Polymerase chain reaction was positive for COVID-19 infection, however, there was no evidence of lung parenchymal involvement or hyper-inflammation. Based on consensus from a multidisciplinary team, aspiration thrombectomy was attempted to treat this extreme case of VTE, however, the patient died during the procedure. This case raises awareness to the most catastrophic form of VTE, presenting in an early phase of COVID-19 infection without the typical hyper-inflammation and severe lung injury associated with development of COVID-related coagulopathy. It also serves to inform on the critical role echocardiography has in the comprehensive evaluation and re-evaluation of hospitalized patients with COVID-19, and the importance of a multidisciplinary organized approach in clinical decision-making for this complex and poorly understood disease and its sequelae. • To recognize that mobile clot in transit is associated with a high mortality and likely under-recognized in COVID-19 patients. • To highlight the importance of a multidisciplinary team approach to pulmonary embolism and COVID-19. The novel coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the healthcare system across the world. Other than its primary pathology of severe respiratory disease, COVID-19 is also associated with a coagulopathy favouring thrombosis over bleeding, which imparts a poor prognosis. 1,2 Clot in transit (CIT) is considered a rare entity, a most severe form of venous thromboembolism (VTE), and is a medical emergency carrying a higher mortality than isolated pulmonary embolism (PE). 3, 4 The incidence of this phenomenon in COVID-19 is unknown and likely under-recognized, and if significant would influence the diagnostic and therapeutic approaches to these patients. A 70-year-old Hispanic female was brought to the emergency department after a syncopal episode, following 2 days of progressive weakness, polyuria, and elevated blood glucose. Syncope occurred upon standing and was witnessed by her family. The patient regained consciousness immediately. She denied fever, chills, sore throat, cough, chest pain, or dyspnoea. Initial blood pressure was 84/ 55 mmHg, pulse 72 b.p.m., oxygen saturation 88% on room air, respiratory rate 16/min, and temperature 36.6 C. Physical exam was unremarkable, including no jugular venous distension (JVD), normal heart and lung sounds, and no peripheral oedema. The patient had a history of hypertension, hyperlipidaemia, diabetes, and supraventricular tachycardia treated successfully with ablation. She denied recent travel or contact with a known COVID-19 patient. Blood pressure and oxygenation improved rapidly with intravenous fluids and supplemental oxygen. She was admitted to telemetry and treated with hydration, insulin, antibiotics, and prophylactic dose anticoagulation. Droplet precautions and contact isolation were ordered for suspected COVID-19 infection. The differential diagnosis included hypovolaemia due to diabetic ketoacidosis and sepsis. Syncope and hypoxaemia in a patient with a normal lung exam raised the suspicion for acute PE. Other causes of syncope and transient hypotension such as myocardial infarction, arrhythmia, and heart failure were also considered. Underlying COVID-19 was also suspected, given it was the peak of the COVID-19 pandemic in New York City (NYC), when the clinical behaviour of the virus was still mostly unknown. Chest X-ray ( Figure 1 ) and head computed tomography were unremarkable. Electrocardiogram showed sinus rhythm at 80 b.p.m. with an S1, Q3, T3 pattern, prolonged QTc, and T-wave inversions across the precordium ( Figure 2 ). Initial laboratory testing revealed hyperglycaemia (580 mg/dL), elevated anion gap, serum creatinine (1.6 mg/dL), lactate (7.5 mml/L), D-dimer (2,153 ng/mL), C-reactive protein (8.6 mg/L), and pro-BNP (14 042 pg/mL). INR was 1.2. Serial troponin T-tests were negative. Urine was positive for ketones and white cells. Initial nasopharyngeal swab for COVID-19 was negative. Other findings are presented in Table 1 . Bedside echocardiogram revealed a moderately dilated right ventricle with mild hypokinesis, without thrombus, and elevated right ventricular systolic pressure (67 mmHg). Patient remained comfortable and haemodynamically stable with a saturation of 98% on 3 L of oxygen. The next morning dyspnoea and desaturation ensued (93% on 3 L). Pulse was 80 b.p.m. and blood pressure 132/78 mmHg. and bilateral filling defects involving all lobes with notable thrombus in the right atrium extending into the right ventricle ( Figure 3) . Repeat echo revealed a highly mobile CIT (Figure 4 , Video 1). Repeat nasopharyngeal swab for COVID-19 was positive. Therapeutic dose anticoagulation with intravenous heparin (5000 unit bolus followed by 1260 units per hour) was started and the patient was transferred to the intensive care unit (ICU). She was evaluated by the multidisciplinary institutional Pulmonary Embolism Response Team (PERT) and given concurrent illness and comorbidities, percutaneous aspiration thrombectomy with adjunctive intra-pulmonary and catheter-directed thrombolysis was recommended. Foregoing general anaesthesia which has known risks in this setting, an AngioVac device (Angiodynamics, Latham, NY, USA) was advanced on suction from a femoral venous approach. The patient was given a total of 13 000 units of heparin intravenously to achieve an activated clotting time above 300. The patient decompensated after initial successful aspiration. Despite further rescue thrombectomy with the Inari FlowTriever device (Inari Medical, Irvine, CA, USA) and administration of intra-pulmonary and systemic thrombolysis the patient arrested and eventually died. Early in the COVID-19 pandemic, NYC hospitals were inundated with COVID-19 infected patients, which in its most severe form progressed to acute respiratory distress syndrome, renal failure, and associated cardiovascular and neurologic sequelae. 5 Usually these complications were seen in the second phase of the illness (7-10 days after symptom onset), triggered by a hyper-immune response associated with a markedly elevated D-dimer. 6 Along with this was a newly described 'COVID associated coagulopathy' which led to increasingly observed thrombosis due to inflammation-induced coagulopathy and was associated with a poor prognosis. 1,2 Anticoagulation with heparin (mostly prophylactic dosing) appeared to confer a lower mortality in a subset of patients with very severe COVID-19 who had extreme elevations of D-dimer. 7 Others reported increased rates of VTE in patients with COVID-19 in the ICU, despite the use of prophylactic anticoagulation. [8] [9] [10] [11] A recent report describing profound haemodynamic collapse due to acute cor pulmonale in five patients in an ICU over a 48-h period suggested that obstructive shock from thromboembolism may have been responsible for the sudden decline, but could not be confirmed in all patients. All were on prophylactic or full-dose anticoagulation, and two of the five patients had evidence of intracardiac thrombus on echo at the time of collapse. 12 Additionally, in another report, right ventricular dilatation identified by echocardiography in patients hospitalized with COVID-19 was independently associated with increased mortality. 13 A CIT, as seen in our case, in a patient already diagnosed with saddle PE and right ventricular dysfunction could rapidly lead to catastrophic shock and death, if undiagnosed and untreated. We also observed three additional cases at our institution of CIT in COVID-19 patients that presented in the later phases of the disease with profound haemodynamic and respiratory collapse. Despite the high mortality rate associated with CIT, though, there are no recommendations on how best to treat CIT in the most up to date ESC guidelines. This likely reflects the paucity of evidence and consensus on management of this phenomenon. Involvement of a multidisciplinary team to manage PE is encouraged in the new guidelines to meet these types of concerns. 14 Combining the conundrums of COVID-19 infection with those of suspected or confirmed PE, especially with CIT, merges two clinical entities that lack robust data to guide decision-making. Pulmonary Embolism Response Teams are uniquely positioned to address this scenario as they can respond rapidly and bring a group of multidisciplinary experts together to provide consensus based and individualized recommendations. A modified PERT algorithm to address some of the unique challenges posed by VTE in the setting of COVID-19 was recently described. 15 Hence, we utilized our multidisciplinary PERT to improve our clinical decisionmaking and come to a rapid consensus on the best management approach for this patient. We are unaware of any reports of the occurrence of such an extreme thrombotic venous event in the absence of severe lung injury and the hyper-inflammation typically linked to COVID-associated coagulopathy. Both VTE and CIT occurred in the first phase of disease when inflammation was modest, and D-dimer was only moderately elevated, raising the question of whether other mechanisms of thrombosis are more active in the early stages of the disease. Increasing number of reports of arterial macro-thrombosis in milder forms of COVID disease underscores the need to further understand the mechanisms related to COVID-associated coagulopathy. 16, 17 We report a rare case of COVID-19 presenting with saddle PE complicated by development of a highly mobile CIT in the absence of lung parenchymal involvement and hyper-inflammation associated with COVID coagulopathy. It is important to suspect and recognize the signs of VTE and CIT in COVID-19 patients, both in the early and later phases of the illness, and consider a lower threshold for diagnostic imaging and treatment. Our case further informs on the central role echocardiography plays in the comprehensive evaluation and reevaluation of hospitalized patients with COVID-19, especially if we want to advance our understanding and management of the most severe forms of VTE in these patients. Finally, it highlights the importance of a multidisciplinary organized approach in meeting the challenges of clinical decision-making in complex diseases that suffer from a paucity of level 1 data such as PE, CIT, and COVID-19. Dr Shunsuke Aoi trained in Japan (Seirei Hamamatsu General Hospital) and in the USA (Mt Sinai Beth Israel) and is currently training as an interventional cardiology fellow at Jacobi Medical Center and Montefiore Medical Center (Bronx, NY, USA). Supplementary material is available at European Heart Journal -Case Reports online. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. The patient reported in this case is deceased. Despite the best efforts of the authors, they have been unable to contact the patient's next-of-kin to obtain consent for publication. Every effort has been made to anonymise the case. This situation has been discussed with the editors. COVID-19 and its implications for thrombosis and anticoagulation Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Pulmonary embolism with clot in transit: an analysis of risk factors and outcomes Mobile thrombi of the right heart in pulmonary embolism Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study The longitudinal immune response to coronavirus disease 2019: chasing the cytokine storm Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Acute cor pulmonale in critically ill patients with covid-19 Right ventricular dilation in hospitalized patients with COVID-19 infection ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the Right ventricular clot in transit in COVID-19: implications for the pulmonary embolism response team Macrothrombosis and stroke in patients with mild Covid-19 infection Large-vessel stroke as a presenting feature of covid-19 in the young Funding: none declared.